MX2013005966A - Nuevos compuestos de benzofurano. - Google Patents

Nuevos compuestos de benzofurano.

Info

Publication number
MX2013005966A
MX2013005966A MX2013005966A MX2013005966A MX2013005966A MX 2013005966 A MX2013005966 A MX 2013005966A MX 2013005966 A MX2013005966 A MX 2013005966A MX 2013005966 A MX2013005966 A MX 2013005966A MX 2013005966 A MX2013005966 A MX 2013005966A
Authority
MX
Mexico
Prior art keywords
compounds
novel
concerned
formula
benzofurane compounds
Prior art date
Application number
MX2013005966A
Other languages
English (en)
Inventor
Rosa Maria Rodriguez Sarmiento
Juergen Wichmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2013005966A publication Critical patent/MX2013005966A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a nuevos moduladores duales de los receptores 5-HT2A y D3 de fórmula (I) en donde n, x, Y, R1, R2, R3, y R4 son como se describen en la presente, así como también sales y ésteres de los mismos farmacéuticamente aceptables. Además la presente invención está relacionada con la manufactura de los compuestos de fórmula (I), composiciones farmacéuticas que los comprenden y su uso como medicamentos.
MX2013005966A 2010-12-15 2011-12-12 Nuevos compuestos de benzofurano. MX2013005966A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10195231 2010-12-15
PCT/EP2011/072403 WO2012080149A1 (en) 2010-12-15 2011-12-12 Novel benzofurane compounds

Publications (1)

Publication Number Publication Date
MX2013005966A true MX2013005966A (es) 2013-07-15

Family

ID=45218739

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013005966A MX2013005966A (es) 2010-12-15 2011-12-12 Nuevos compuestos de benzofurano.

Country Status (10)

Country Link
US (1) US8877778B2 (es)
EP (1) EP2651929A1 (es)
JP (1) JP2014503519A (es)
KR (1) KR20130126958A (es)
CN (1) CN103261190A (es)
BR (1) BR112013014770A2 (es)
CA (1) CA2819970A1 (es)
MX (1) MX2013005966A (es)
RU (1) RU2013132409A (es)
WO (1) WO2012080149A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2694009A1 (en) * 2007-07-26 2009-01-29 F. Hoffmann-La Roche Ag Dual modulators of 5-ht2a and d3 receptors
CN106518841B (zh) * 2015-09-15 2019-03-05 浙江京新药业股份有限公司 环己烷衍生物或其立体异构体或盐及其制备与应用
JP7015092B2 (ja) 2016-07-28 2022-02-02 塩野義製薬株式会社 ドーパミンｄ３受容体拮抗作用を有する含窒素縮環化合物
US11447484B2 (en) 2018-01-26 2022-09-20 Shionogi & Co., Ltd. Cyclic compound having dopamine D3 receptor antagonistic effect
JPWO2019146739A1 (ja) 2018-01-26 2021-01-07 塩野義製薬株式会社 ドーパミンｄ３受容体拮抗作用を有する縮環化合物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776963A (en) 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
DK60693D0 (da) 1993-05-26 1993-05-26 Novo Nordisk As Kemiske forbindelser, deres fremstilling og anvendelse
DE4333254A1 (de) * 1993-09-30 1995-04-06 Merck Patent Gmbh Piperidine und Piperazine
CN1154105A (zh) * 1994-06-08 1997-07-09 H·隆德贝克有限公司 4-芳基-1-(二氢化茚甲基、二氢苯并呋喃甲基或二氢苯并噻吩甲基)哌啶、-四氢吡啶或哌嗪类化合物
IL131243A (en) 1997-02-07 2004-02-19 Aventis Pharma Inc History - (4 Piperidinyl) - 2-1H - Benzofiran, their preparation and pharmaceutical preparations containing them
TW530054B (en) 1997-09-24 2003-05-01 Duphar Int Res New piperazine and piperidine compounds
AU3327399A (en) 1998-02-09 1999-08-23 Duphar International Research B.V. Benzisoxazole derivatives having d4-antagonistic activity
GB0117577D0 (en) * 2001-02-16 2001-09-12 Aventis Pharm Prod Inc Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D receptor ligands
WO2002066469A2 (en) 2001-02-16 2002-08-29 Aventis Pharmaceuticals Inc. Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands
CA2438264A1 (en) 2001-02-16 2002-08-29 Aventis Pharmaceuticals Inc. Heterocyclic substituted carbonyl derivatives and their use as dopamine d3 receptor ligands
GB0117950D0 (en) 2001-02-16 2001-09-19 Aventis Pharma Inc Novel heterocyclic urea derivatives andd their use as dopamine D3 receptor ligands
BR0314393A (pt) 2002-09-17 2005-07-19 Warner Lambert Co Piperazinas heterocìclicas substituìdas para o tratamento de esquizofrenia
WO2004100954A1 (en) 2003-05-16 2004-11-25 Pfizer Products Inc. Treatment of psychotic and depressive disorders
CA2525868A1 (en) 2003-05-16 2004-11-25 Pfizer Products Inc. Anxiety treatments with ziprasidone
HUP0500170A3 (en) 2005-02-03 2007-11-28 Richter Gedeon Nyrt Piperazine derivatives, process for producing them and pharmaceutical compositions containing them
AU2007216563B2 (en) * 2006-02-17 2012-08-09 F. Hoffmann-La Roche Ag Benzoyl-piperidine derivatives as 5HT2/D3 modulators
EP1870405A1 (en) 2006-06-22 2007-12-26 Bioprojet Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands
ES2401663T3 (es) 2006-10-31 2013-04-23 F. Hoffmann-La Roche Ag Derivados éter moduladores duales de los receptores de 5-HT2a y D3
CA2694009A1 (en) * 2007-07-26 2009-01-29 F. Hoffmann-La Roche Ag Dual modulators of 5-ht2a and d3 receptors
ES2402875T3 (es) 2008-09-22 2013-05-10 F. Hoffmann-La Roche Ag Moduladores de receptores de D3 y de 5-HT2a
CA2736724A1 (en) 2008-09-23 2010-04-01 F.Hoffmann-La Roche Ag Benzo[d]isoxazol-3-yl-piperazin derivatives useful as modulators of dopamine d3 receptors
WO2010034656A1 (en) 2008-09-23 2010-04-01 F. Hoffmann-La Roche Ag Isoxazolo[4,5]pyridin-3-yl-piperazin derivatives useful as modulatorsof dopamine d3 receptors
WO2010034648A1 (en) 2008-09-23 2010-04-01 F. Hoffmann-La Roche Ag Pyridinylpiperazin derivatives useful as modulators of dopamine d3 receptors
US8586579B2 (en) 2010-06-21 2013-11-19 Hoffmann-La Roche Inc. Anellated pyridine compounds

Also Published As

Publication number Publication date
US8877778B2 (en) 2014-11-04
US20120157449A1 (en) 2012-06-21
RU2013132409A (ru) 2015-01-20
KR20130126958A (ko) 2013-11-21
CA2819970A1 (en) 2012-06-21
BR112013014770A2 (pt) 2016-10-04
CN103261190A (zh) 2013-08-21
JP2014503519A (ja) 2014-02-13
EP2651929A1 (en) 2013-10-23
WO2012080149A1 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
MX2014000626A (es) Nuevos derivados de indol sustituidos como moduladores de gamma secretasa.
MX2014014229A (es) Pirrolidina-2-carboxamidas sustituidas.
MX2011011484A (es) Derivados de isoxazol-piridina como moduladores del acido gamma-aminobutirico.
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
MX2015017345A (es) Compuestos para tratar atrofia muscular espinal.
MX347706B (es) Derivados de triazol y su uso para trastornos neurologicos.
MX2012008259A (es) Novedosos derivados biciclicos de triazol sustituidos como moduladores de gamma secretasa.
PH12014501542A1 (en) Substituted pyrrolidine -2- carboxamides
EA201490320A1 (ru) Соединения тетрагидропиридопиридина и тетрагидропиридопиримидина и их применение в качестве модуляторов рецептора c5a
MX2013008531A (es) Nuevos compuestos de benzodioxol-piperazina.
IN2014CN04530A (es)
EA201270216A1 (ru) Фармацевтический состав
MX2011007737A (es) Derivados de hidroximetil isoxazol como moduladores de acido gamma-aminobutirico a.
MY187718A (en) Pharmaceutical formulations
MX2011013884A (es) Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas.
EA201200471A1 (ru) Простые эфирные производные бициклических гетероарилов
MX2011011303A (es) Derivados de isoxazol.
BR112013000189A2 (pt) compostos de piridina anelados
MA33948B1 (fr) Dérivés d'acide 3-hétéroaroylamino-propionique substitues par oxygène et leur utilisation en tant qu'agents pharmaceutiques.
EA201400854A1 (ru) 4-(бензоимидазол-2-ил)тиазольные соединения и родственные аза производные
CA2891755C (en) Substituted pyrido-piperazinone derivatives as gamma secretase modulators
TW200738627A (en) Trialkylsilyl-indoles
MX345544B (es) Derivados de triazol como ligandos para receptores de acido gamma-aminobutirico (gaba).
MX2013005966A (es) Nuevos compuestos de benzofurano.
WO2014062838A3 (en) Pkm2 modulators and methods for their use

Legal Events

Date Code Title Description
FA Abandonment or withdrawal